🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Torrent Pharmaceuticals Limited TORNTPHARM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.torrentpharma.com

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.

READ MORE ›
₹4,410.80
+40.76% 1Y

Market & Price

Market Cap
₹1.49 L Cr
Current Price
₹4,410.80
High / Low (52W)
₹4,572.60 / ₹3,100.61
Beta
0.14

Valuation

Stock P/E
68.96
Industry PE
37.60
Forward P/E
46.46
PEG Ratio
-
Book Value
₹249.47
Price to Book
17.68
P/S
10.68
EV/EBITDA
37.56
Dividend Yield
0.86%

Profitability & Returns

ROCE
9.06%
ROE
16.98%
ROA
7.25%
Profit Margin
15.47%
Op Margin
20.21%
EPS (Latest Qtr)
₹11.51
EPS (TTM)
₹63.96

Balance Sheet & Liquidity

Debt/Equity
0.85
Quick Ratio
0.61
Current Ratio
1.13
Debt
₹15,025.00 Cr
Total Assets
₹44,312.00 Cr
Current Assets
₹9,392.00 Cr
Working Capital
₹1,049.00 Cr

Ownership

Promoter Holding
71.19%
Chg in Prom Hold
-
FII / Inst Holding
15.82%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹1.71 L Cr
Total Revenue (TTM)
₹13,980.00 Cr
EBITDA
₹4,559.00 Cr
Free Cash Flow
₹2,277.78 Cr
Operating Cash Flow
₹3,023.00 Cr
Shares Outstanding
₹33.84 Cr
Gross Margin
75.77%
Payout Ratio
54.76%

Growth (CAGR)

Revenue 5Y
13.27%
Profit 5Y
20.21%
Revenue (YoY)
41.80%
Earnings (YoY)
-21.80%

PROS

  • Compounding revenue at 13.3% over 5 years.
  • Profit CAGR of 20.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 69.0.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
5 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
8 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 965.10 65.34 ₹93,927.75 Cr 0.16% 12.70% 14.33% 23.10% 9.34%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -2,762.00 Cr2,909.00 Cr3,128.00 Cr3,246.00 Cr3,251.00 Cr4,128.00 Cr
Cost of Revenue -673.00 Cr731.00 Cr774.00 Cr800.00 Cr799.00 Cr1,015.00 Cr
Gross Profit -2,089.00 Cr2,178.00 Cr2,354.00 Cr2,446.00 Cr2,452.00 Cr3,113.00 Cr
Operating Expenses -1,374.00 Cr1,415.00 Cr1,523.00 Cr1,567.00 Cr1,570.00 Cr2,265.00 Cr
Operating Income -715.00 Cr763.00 Cr831.00 Cr879.00 Cr882.00 Cr848.00 Cr
EBITDA -947.00 Cr922.00 Cr995.00 Cr1,043.00 Cr1,065.00 Cr1,273.00 Cr
Interest Expense -57.00 Cr56.00 Cr56.00 Cr48.00 Cr45.00 Cr236.00 Cr
Pretax Income -691.00 Cr665.00 Cr738.00 Cr791.00 Cr814.00 Cr529.00 Cr
Tax Provision -188.00 Cr167.00 Cr190.00 Cr200.00 Cr179.00 Cr165.00 Cr
Net Income -503.00 Cr498.00 Cr548.00 Cr591.00 Cr635.00 Cr389.00 Cr
Diluted EPS 13.3714.8814.7116.1917.4518.7711.51

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -9,463.69 Cr10,562.31 Cr11,317.00 Cr13,753.00 Cr
Cost of Revenue -2,827.69 Cr2,787.73 Cr2,776.00 Cr3,388.00 Cr
Gross Profit -6,636.00 Cr7,774.58 Cr8,541.00 Cr10,365.00 Cr
Operating Expenses -4,495.98 Cr5,202.23 Cr5,615.00 Cr6,925.00 Cr
Operating Income -2,140.02 Cr2,572.35 Cr2,926.00 Cr3,440.00 Cr
EBITDA -2,881.43 Cr3,500.04 Cr3,720.00 Cr4,376.00 Cr
Interest Expense -332.24 Cr352.63 Cr252.00 Cr385.00 Cr
Pretax Income -1,847.16 Cr2,352.11 Cr2,673.00 Cr2,872.00 Cr
Tax Provision -601.93 Cr695.73 Cr762.00 Cr734.00 Cr
Net Income -1,245.23 Cr1,656.38 Cr1,911.00 Cr2,163.00 Cr
Diluted EPS 22.9636.7948.9456.47-

Compounded Sales Growth

5 Years:13.27%
1 Year:41.80%

Compounded Profit Growth

5 Years:20.21%
1 Year:-21.80%

Stock Price Performance

1 Year:+40.76%
6 Months:+19.43%
3 Months:+2.40%
1 Month:+4.24%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -15,011.85 Cr15,060.58 Cr14,989.74 Cr44,312.00 Cr
Current Assets -5,313.72 Cr5,611.48 Cr5,622.57 Cr9,392.00 Cr
Cash & Equivalents -508.53 Cr835.14 Cr573.48 Cr1,117.00 Cr
Inventory -2,229.64 Cr2,279.07 Cr2,541.25 Cr3,138.00 Cr
Receivables -1,943.82 Cr1,844.30 Cr1,866.45 Cr3,031.00 Cr
Total Liabilities -8,813.78 Cr8,204.43 Cr7,399.05 Cr26,727.00 Cr
Current Liabilities -5,447.30 Cr5,425.25 Cr4,717.19 Cr8,343.00 Cr
Long Term Debt -2,496.22 Cr1,603.78 Cr1,191.75 Cr11,651.00 Cr
Total Debt -5,368.56 Cr4,021.94 Cr3,202.32 Cr15,025.00 Cr
Total Equity -6,198.07 Cr6,856.15 Cr7,590.69 Cr8,389.00 Cr
Shares Outstanding -33.84 Cr33.84 Cr33.84 Cr33.84 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -2,368.13 Cr3,266.08 Cr2,585.00 Cr3,023.00 Cr
Investing Cash Flow --2,415.31 Cr-167.90 Cr-540.00 Cr-12,713.00 Cr
Financing Cash Flow -77.36 Cr-2,779.64 Cr-2,298.00 Cr10,151.00 Cr
Capital Expenditure --573.94 Cr-432.78 Cr-611.00 Cr-677.00 Cr
Free Cash Flow -1,794.19 Cr2,833.30 Cr1,974.00 Cr2,346.00 Cr
Net Change in Cash -30.18 Cr318.54 Cr-253.00 Cr461.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -70.1%73.6%75.5%75.4%
Operating Margin % -22.6%24.4%25.9%25.0%
Net Margin % -13.2%15.7%16.9%15.7%
ROE % -20.1%24.2%25.2%25.8%
ROCE % -22.4%26.7%28.5%9.6%

Shareholding Pattern

Insiders
71.19%
Institutions
15.82%
Public Float
54.92%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TORNTPHARM

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space